Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study.

Abstract

Dianhydrogalactitol was administered intravenously to patients with advanced or recurrent gynecologic malignancies on a weekly schedule. The initial dosage was 60 mg/m2 with escalation to 75 mg/m2 if there were no adverse effects. Forty-two patients with ovarian epithelial adenocarcinoma (OEA) and forty-one patients with squamous carcinoma of the cervix… (More)

Topics

Cite this paper

@article{Stehman1983PhaseIT, title={Phase II trial of galactitol 1,2:5,6-dianhydro (NSC 132313) in the treatment of advanced gynecologic malignancies: a Gynecologic Oncology Group study.}, author={F B Stehman and Jochen Blom and John A. Blessing and Cassandra Ehrlich and Connor J Mangan}, journal={Gynecologic oncology}, year={1983}, volume={15 3}, pages={381-90} }